Xinjiang Bai Hua Cun Pharma Tech Co Ltd
Xinjiang Bai Hua Cun Pharma Tech Co Ltd is a Chinese pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products.
Business. Xinjiang Bai Hua Cun Pharma Tech Co Ltd (600721.SS) is a healthcare company engaged in biotechnology and medical research. The firm is headquartered in China and primarily listed on the Shanghai Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Xinjiang Bai Hua Cun Pharma Tech Co Ltd (600721.SS) is a healthcare company engaged in biotechnology and medical research. The firm is headquartered in China and primarily listed on the Shanghai Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
The company maintains a strong liquidity position, with a current ratio of 2.29, indicating that it has more than twice the current assets to cover its current liabilities. However, its liquidity risk is assessed as medium, primarily due to a negative net cash position after subtracting total debt. The price-to-book ratio of 3.57 suggests that the market values the company at a premium to its book value, while the price-to-earnings ratio of 70.41 indicates a high valuation relative to earnings.
In terms of profitability, the company's return on equity (ROE) of 5.07% and return on assets (ROA) of 3.71% are below the typical thresholds for high-performing pharmaceutical firms, suggesting that it is not generating strong returns relative to its equity and asset base. The gross profit margin of 39.6% (calculated as gross profit of 153.7 million CNY on revenue of 388.3 million CNY) is in line with industry norms, but the operating margin of 11.3% (calculated as operating income of 44.0 million CNY) is relatively modest.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of segment or geographic diversification increases the risk of revenue volatility due to market-specific or regulatory changes.
The company's growth trajectory is not clearly defined in the provided data, as there are no forward-looking revenue projections or historical growth rates available. The absence of a clear growth narrative makes it difficult to assess the company's long-term potential.
The risk assessment indicates a low dilution risk, with no significant dilution potential identified in the basic shares outstanding. However, the company's capital structure includes a small amount of long-term debt (37.5 million CNY), which could increase financial risk if not managed prudently. No recent events, such as filings or transcripts, are provided in the data to inform the company's strategic direction or operational performance.
- The company has a high price-to-earnings ratio, indicating a premium valuation relative to earnings.
- The company's return on equity and return on assets are below typical thresholds for high-performing pharmaceutical firms.
- The company's liquidity position is strong, but its net cash position is negative after subtracting total debt.
- The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
- The company's growth trajectory is not clearly defined in the provided data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Xinjiang Bai Hua Cun Pharma Tech Co Ltd Market data — financials · 2026-05-27